Dr. Ümit Dereli and Cengiz Aydın of the Association of Research-Based Pharmaceutical Companies (AIFD) inTurkey discuss significant recent changes in the Turkish ecosystem, including the improving recognition of the country’s regulatory agency, new pricing and localization policies, AIFD’s contribution to Turkey’s 11th Development Plan, and the ambition to make Turkey “a globally competitive power in the pharma industry and across all parts of the value chain.”
What would you highlight to our international readers as the most significant changes that have been shaping the Turkish pharmaceutical ecosystem over the past years?
"We can already feel that TITCK’s improvements have had a positive impact on the Turkish ecosystem at large and could usher in evermore-promising outcomes for the future of Turkey’s pharmaceutical industry"
